Inozyme Pharma (NASDAQ:INZY) Downgraded to "Hold" Rating by Wedbush

Inozyme Pharma (NASDAQ:INZY - Get Free Report) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating in a report released on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma's Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.79) EPS.

INZY has been the subject of several other reports. Jefferies Financial Group reissued a "hold" rating and issued a $4.00 price target (down from $15.00) on shares of Inozyme Pharma in a report on Friday. Piper Sandler cut their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Needham & Company LLC downgraded shares of Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a report on Friday. Wells Fargo & Company reissued an "equal weight" rating and issued a $4.00 price target on shares of Inozyme Pharma in a report on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Inozyme Pharma in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.75.

Inozyme Pharma Stock Up 178.2%

Shares of NASDAQ:INZY opened at $3.95 on Friday. The firm has a fifty day moving average price of $1.09 and a two-hundred day moving average price of $1.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a one year low of $0.72 and a one year high of $6.24. The company has a market cap of $255.02 million, a price-to-earnings ratio of -2.53 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Trading of Inozyme Pharma

A number of hedge funds have recently made changes to their positions in INZY. JPMorgan Chase & Co. raised its position in Inozyme Pharma by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company's stock worth $151,000 after purchasing an additional 6,851 shares during the period. Palumbo Wealth Management LLC raised its position in Inozyme Pharma by 52.3% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company's stock worth $64,000 after purchasing an additional 7,995 shares during the period. American Century Companies Inc. raised its position in Inozyme Pharma by 11.6% in the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company's stock worth $220,000 after purchasing an additional 8,263 shares during the period. Geode Capital Management LLC raised its position in Inozyme Pharma by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company's stock worth $3,268,000 after purchasing an additional 8,450 shares during the period. Finally, Deutsche Bank AG raised its position in Inozyme Pharma by 29.1% in the 4th quarter. Deutsche Bank AG now owns 40,215 shares of the company's stock worth $111,000 after purchasing an additional 9,055 shares during the period. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.